Advertisement
Advertisement
U.S. markets open in 8 hours
Advertisement
Advertisement
Advertisement
Advertisement

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6100-0.0300 (-0.82%)
At close: 04:00PM EDT
3.6100 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Sign in to post a message.
  • D
    Dushyant
    Due to the economic crisis that always comes up 🇺🇸🇺🇸 the best thing to be on every wise individuals mind or list is to invest in different streams of income that's not depending on the government to create funds💰👍
  • S
    StockStuffer
    It is only a matter of time until a $GOOG $IBM $NVDA $AMZN $META or $TSLA 's Elon Musk decide to go all in using Artificial Intelligence AI in medicine. At that point a broad range of smaller companies that use AI for specific medical reasons will be acquired to create a mesh of interacting AI to detect, monitor, and treat patients ailments. Tiny companies like $ICAD that use AI to detect cancer in imaging will be targets when this happens. It's only a matter of time until this happens.
  • i
    ikram
    Wooow
    Finally it’s breaking all the resistances.
    Bullish
  • J
    John1
    Where the F is ICAD going? $2.99 earlier today and when you view the 1 & 3 month charts it's trying its hardest to crash for good. Are we now looking at a full blown buyout-on-the-cheap for another company?
    Bearish
  • W
    Wise Owl
    My close, medical friends are murmuring that ICAD is very much on the radar of numerous medical technology companies and large medical-type corporations. Be ready for a nice pop soon. I've been loading up the additional shares on the big dips.
    Bullish
  • J
    J
    I have been in and out since the howtek days, remember Scott Par. Irrelevant at this point but paints my history picture in a nutshell.

    Covid gummed up some of the works, management fell short on time frames, approval processing for reimbursements being ridiculously stubborn in some cases suspiciously protective of inferior procedures(ex Mohs). The path forward has been hindered and impeded more than in any other company I have known. Is it iCADs incompetence? Is it big money insurance not wanting cheaper better solutions moving in? I don't know, likely a little bit of both.

    The bottom line is the bottom line. Will iCAD have enough the next few years to accomplish their goal of profitiblity with out dilution. I was here for the 1 for 5 split which brough us back to 5 mill and changes shares outstanding. Since that time shares outstanding has grown back to 25.11 million shares. You can do the math.

    IMHO iCAD insiders need to buy( not give themselves) shares has a show of faith and confidence. I did see 30k purchased in dec but come on guys. In the last proxy they asked us to grant them more shares for themselves and I said no,,, no more until go beyond break even for a year. If they believe in themselves as much as they want us to believe in them they should be buying with both hands but alas they have so many hand me down shares why bother.

    Stacey Stevens has a chance to make a name for herself here; she is capable, hard working and competent, unfortunately that does not always mean successful.

    So, I am still here mostly for the technology, the balance sheet( watching closely), and the US is still capable of doing the right thing regarding patients, technology and medicine/therapeutics. The last part is long overdue.
  • J
    John1
    Is ICAD a potential buyout target or are they definitely in for the permanent long haul?
  • A
    Andy
    Congrats to the folks at Icad for the FDA's approval for ProFound 3.0 version for 3D mammography.
    Faster reads for the medical professionals and more accurate for the patients and fewer false positives.
    Well done Michael Klein and team.
  • B
    Bill
    I've been holding this for bout 15 years. Don't even know why anymore, I guess just from habit. There's been a few times over the years listening to CC I actually thought the management was heading in the right direction to profitability but they never seem to be able to flip to being profitable. The misses on EPS and rev this qtr wasn't huge, but judging from the 10X normal volume of selling (and buying) at 30% drop in price it's seems many investors are feeling frustrated like me. Normally, I'd be buying the huge dip but this time I was so frustrated I decided NOT to add more position in this company. I know that sounds like a decision based on emotion but I'm not one of the younger investors looking to save the planet or improve everyone's health or some other do gooder thing, I'm old school and invest expecting to MAKE money for ME at some point! I'm sorry to those who find making a profit OFFENSIVE which seems to be the attitude nowadays, but I'd rather drop a dollar in the basket at church and at the red cross Christmas bucket instead of saying I gave at ICAD, the other non profit organization!
  • S
    StockStuffer
    HIFU just had a CPT-1 code which is good for the likes of EDAP another of my cancer treatment/cure plays. It only a matter of time before ICAD and brachytherapy comes along. HIFU never had this coding before so its good for all non-incumbent solutions.
  • J
    John1
    ICAD is on its way back up, so if you plan to get bargain pricing today, act quickly. It's gone from a low of 10.36 to 11.60 in just a few hours. GLTA you longs. Go ICAD
    Bullish
  • J
    John1
    Just wow!
    It might be a major buying opportunity today seeing as it's down 30%. Opinions?
  • J
    Joann M
    so dissappointing. I went and bought more a few months ago and now am stuck with the loss. Im not abig investor but this was big for me and they sounded so promising.
  • W
    William
    Share price reacting well... Message board is quiet... I am not at full position and w/the lack of pumpers/bashers its probably still ok to add even w/the run up as of late. I would rather average up than down in my experience. Just my $0.02. GL
  • J
    John1
    Any crystal ball predictions for earnings after the close on Aug. 5th? I predict a great report.
  • G
    GERRY
    I think a refreshing conference call would be as follows. " Folks, we are trying very hard but we just can't figure out how to get it done yet. So we agree with you: We stink. Since we know how insulting you find it to see your investment depreciate while we cash in options that we get for next to nothing, we've instructed some of our folks to stay away from the trough until we can reward our long suffering stockholders with meaningful results. That is all"
  • B
    Bill
    When the 12 year CEO gets "Retired" just a couple days before the scheduled announcement of Q3 earnings, can that be taken as a hint of Q3 numbers not being very good?
  • s
    s_cap
    On October 26, 2018, Dr. Lawrence Howard and Mr. Steven Rappaport each submitted his resignation from the Board of Directors
  • s
    sea
    Well, well finally the best? AI medical software is getting some attention after all? License to Hologic and... boom...
  • s
    sea
    PM boost from....JMP Securities analyst David Turkaly initiated coverage of iCAD with an Outperform rating and $15 price target. The analyst is positive on the company's platform focus of improving detection of early stage cancers, stating its products offer "meaningful benefits to patients, customers, and healthcare providers alike". Turkaly also cites "notable progress" made by iCAD in 2019 under CEO Mike Klein, with the company posting a double-digit, top-line growth driven by the successful commercial launch of its ProFound AI detection produc
Advertisement
Advertisement